Tamakoshi K, Kikkawa F, Hasegawa N, Ishikawa H, Mizuno K, Kawai M, Tomoda Y
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
Gynecol Obstet Invest. 1995;39(2):125-9. doi: 10.1159/000292393.
CA125 II, an improved version of the conventional CA125 was compared with CA125 as to which was more useful in gynecologic disease. In the diagnosis of tumors around the adnexal field (primary epithelial ovarian cancer, metastatic ovarian cancer, benign ovarian tumor and endometrial cyst), CA125 II showed the same sensitivity and specificity as CA125. CA125 II also has high simultaneous reproducibility in the low concentration area. The examination by the receiver operating characteristic curve revealed that CA125 II has higher precision than that of CA125 when it is used for the screening test. In conclusion, CA125 II is a better tumor marker than conventional CA125.
CA125 II是传统CA125的改良版本，就其在妇科疾病中哪一个更有用进行了比较。在附件区周围肿瘤（原发性上皮性卵巢癌、转移性卵巢癌、良性卵巢肿瘤和子宫内膜囊肿）的诊断中，CA125 II显示出与CA125相同的敏感性和特异性。CA125 II在低浓度区域也具有高同时重现性。通过接受者操作特征曲线检查发现，当用于筛查试验时，CA125 II比CA125具有更高的精度。总之，CA125 II是一种比传统CA125更好的肿瘤标志物。
